Takeda ADHD settlement overview:
- Who: Takeda Pharmaceutical Co. subsidiaries Takeda Pharmaceuticals U.S.A., Baxter International, Viropharma Inc., Shire PLC and Takeda Pharmaceuticals America agreed to a settlement with the Texas Attorney General’s Office.
- Why: The settlement resolved claims the companies improperly marketed the ADHD drug Vyvanse.
- Where: Takeda reached the settlement with the state of Texas.
Six subsidiaries of Takeda Pharmaceutical Co. agreed to pay a combined $42 million to resolve claims the drug manufacturers violated the Texas Medicaid Fraud Protection Act (TMFPA) by improperly marketing the ADHD drug Vyvanse.
The state of Texas claimed the Takeda subsidiaries either directly or indirectly provided nursing and reimbursement services for certain pharma drugs to Medicaid providers in the state, Law360 reports.
The Takeda subsidiaries, including Takeda Pharmaceuticals U.S.A. and Baxter International, among others, were also accused of paying off clinical nurse educators to refer or recommend Vyvanse to providers between January 2014 and December 2015.
The Texas Attorney General’s Office says the allegations were initially part of a whistleblower lawsuit that was brought against the Takeda subsidiaries under the TMFPA’s qui tam provisions, Law360 reports.
Takeda subsidiary Shire previously agreed to settle claims
The four other Takeda subsidiaries in the settlement are Viropharma Inc.; Shire PLC, which reportedly agreed to pay $56.5 million in 2014 to resolve similar claims it improperly marketed an ADHD drug; Baxalta Inc.; and Takeda Pharmaceuticals America.
The Shire settlement, reached with the Department of Justice (DOJ), put to bed claims the company violated the False Claims Act by allegedly improperly promoting and marketing five drugs, including Vyvanse, used to treat ADHD and ulcerative colitis, Law360 reports.
Takeda had not yet acquired Shire at the time of the 2014 settlement. The acquisition was finalized in January 2019, only eight months after the buy offer was accepted.
In another case involving Texas, the DOJ filed a lawsuit against the state and its governor Greg Abbott over claims they broke the law by placing a floating barrier in the Rio Grande to try and deter migrants from attempting to cross the border into the state.
Do you believe the Takeda subsidiaries improperly marketed the ADHD drug Vyvanse? Let us know in the comments.
Don’t Miss Out!
Check out our list of Class Action Lawsuits and Class Action Settlements you may qualify to join!
Read About More Class Action Lawsuits & Class Action Settlements:
38 thoughts onTakeda reaches $42M settlement over ADHD drug marketing
I take Vyvanse after taking other several other ADHD medications over the last 30 years and I do agree that it has helped me from instinctually reacting impulsively w/o first thinking through my own reactions first. And it has truly helped me take control of my extreme ADHD impulsivity & even helped me with having fewer Bi-polar episodes. That being said, if taken as directed and responsibly as needed, I have found Vyvance to be extremely effected for me personally for myself & I can also say I have not detected any kind of side effects from the medication itself .
Hope this truly helps others
Vyvanse ruined my life, my marriage, and my children’s life. And caused me so many medical problems, physically, mentally ,and emotionally. I ended up in a psychiatric ward in the hospital due to the complications and the negligence of this pharmasuitical company and the doctors who prescribed it to me for over 10 years
Been taking vyvanse for 10 years. This needs resolved.
Took Vyvanse approximately 20 years. Have found he has heart failure. The RX are outrageous and the other medical bills are more than I make in one year. Please reply asap.
Took Vyvanse approximately 20 years. Have found he has heart failure. The RX are outrageous and the other medical bills are more than I make in one year. Please reply asap.
Have taken Vyvanse for a few years, had great results. Less impulsive behavior, better time management and concentration. No problems.